Clinical Trial Update: Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sofosbuvir and daclatasvir for hepatitis C in 200 patients co-infected with HIV has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Daklinza (Daclatasvir)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Tehran University of Medical Sciences | Conditions: Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus | Phase 3 | Status: COMPLETED